TORNTPHARM’s base case projects 12–14% CAGR driven by Brazil/U.S. execution and JB integration, with margins expanding to 33–34% by FY29. Outcomes hinge on GLP-1 timing, Germany resolution, synergy capture, and cost discipline, as structural tailwinds offset cyclical pricing pressures
1–2 minutes
3-Scenario Framework
📊 Base Case (50% Probability)
Key Variables: (1) Ozempic launches in Brazil by late FY27; (2) JB synergies realize as guided (INR 400–450Cr by FY29).
Outcome: Brazil grows at 12–15% CAGR (ex-Semaglutide); U.S. hits $200M revenue by FY27 (20% CAGR). JB’s margin improves to 30% by FY28. Germany stabilizes by Q2 FY27; alternate supplier onboarded in 3 quarters.
Implications: Topline grows at 12–14% CAGR; EBITDA margins expand to 33–34% by FY29. Net debt/EBITDA targets achieved; interest expense declines to INR ~50Cr by FY29. FCF turns positive by FY28.
VBL’s topline hinges on weather normalization and Twizza execution, with 10–15% growth probable; bottomline leverages operating scale and cost absorption, targeting 12–20% EPS upside; margins face cyclical realization pressure but structural backward integration supports 23–26% India EBITDA and 17–20% ex-India EBITDA by 2027.
1–2 minutes
3-Scenario Framework
📊 Base Case (50% Probability)
Key Variables: Normal weather, Twizza synergies on track, snacks scale to ₹500cr.
Outcome: Volumes grow 10–12%; realization improves 2–3% on mix. India EBITDA margins sustain at 24–25%; ex-India margins expand to 17–18%. Free cash flow funds Twizza and brewery; dividend hike likely. Topline: +10–12%; Bottomline: +12–15%.
Motherson FY27 outlook: Revenue growth (8–15%) depends on Greenfield execution and European OEM strength; consumer electronics/aerospace scalability is pivotal. EBITDA margins may swing 50–200 bps from commodity/FX, but efficiencies and ROCE discipline cushion downside. Non-auto expansion (40%+ ROCE) offsets auto cyclicality if execution succeeds.
1–2 minutes
3-Scenario Framework
📊 Base Case (50% Probability)
Key Variables: (1) European OEMs stabilize market share; (2) Greenfields contribute 70% of targeted FY27 revenue; (3) consumer electronics/aerospace scale to 20M units/year by FY28. Outcome: Revenue grows 10–12% YoY in FY27; EBITDA margins expand 50–100 bps on operational efficiencies and FX tailwinds. Leverage remains 1.0–1.2x; ROCE in new ventures hits 35–40%. Implication: Sustainable topline growth; margin expansion offsets cyclical pressures.
KIRLOSENG’s topline growth is structurally tied to HHP/infrastructure demand and export diversification, while margins hinge on execution of high-margin segments (HHP, Defence, Fluid Dynamics) and commodity management—model 13–15% EBITDA as base, with 200 bps sensitivity to order delays or share shifts.
1–2 minutes
3-Scenario Framework
📊 Base Case (50% Probability)
HHP scales as guided (25%+ YoY growth), with NPCIL orders executed on time and data centre traction. LHP stabilizes (incentives offset share loss), and MENA/Africa exports grow 15–20%. Capex absorption aligns with demand; Arka’s retail book expands without material NPA spikes. Topline: 15–18% CAGR; EBITDA margins expand to 13–14% by FY28.
Topline growth hinges on GLP-1/biosimilar launch execution and insulin capacity scaling, while margins and cash flow depend on Syngene’s CRDMO recovery and debt reduction pace—model 12–18% revenue CAGR with 25–28% EBITDA as base, but skew risks to downside on regulatory delays.
1–2 minutes
3-Scenario Framework
📊 Base Case (50% Probability)
Liraglutide/semaglutide launch in EU/Canada by late 2026; insulin capacity doubles on schedule, capturing 15–20% market share in interchangeable segments. Biosimilars grow 15–18% YoY (new launches offset legacy erosion); generics sustain 20%+ growth. Trigger: Regulatory clarity + successful tech transfers. Outcome: Group revenue grows 12–15% YoY; EBITDA margins expand to 26–28%.
BEML’s topline hinges on Rail & Metro execution (15,000-car TAM) and Defense L1 conversions, but near-term capacity and FX risks cap upside; bottomline faces 16–18-month FX headwind and capex drag; margins remain range-bound (100 bps either side) absent supply chain breakthroughs or FX tailwinds.
1–2 minutes
3-Scenario Framework
📊 Base Case (50% Probability)
Key Variables: Bhopal Phase 1 on time; 50% success in metro/LHB tenders; Defense L1 conversions in H1 FY27.
BRITANNIA’s revenue may rise 8–10%, driven by e-commerce and adjacencies, though GST shifts and regional rivals weigh near term. Profit growth depends on commodity stability and margin discipline, with EBITDA at 19–21% if brand spend is balanced; gross margins volatile at 40–44%.
1–2 minutes
3-Scenario Framework
📊 Base Case (50% Probability)
Key Variables: (1) GST transition completes by Q1 FY27, (2) Commodity stability (flour/RPO ±5%). Outcome: Revenue growth stabilizes at 8–10% (volume +5%, GST tailwinds +3–4%). Gross margins sustain at 42–44%; EBITDA margins hold at 19–21% with disciplined brand spend. Adjacencies grow at 20%+ (e-comm penetration reaches 12% by FY27). Cheese shows early turnaround signs; state incentives partially offset. Labor Code costs contained.
Topline likely to sustain 20%+ YoY growth led by paints/B2B, but bottomline hinges on B2B breakeven timing and margin expansion in chemicals/renewables; structural premiumization in paints offsets cyclical chemical pressures, while CAPEX completion unlocks free cash flow from FY27.
Hindalco’s topline growth hinges on Bay Minette/Aditya Refinery execution and LME trends; bottomline volatility driven by Oswego insurance timing and hedge roll-offs; margins resilient in India (structural cost advantage) but Novelis recovery lags until FY28.
1–2 minutes
3-Scenario Framework
📊 Base Case (50% Probability)
Key Variables: Oswego restarts Q1 FY27; Bay Minette Phase 1 on budget/schedule; LME prices flat; Chakla mine operational by 1H FY27.
Outcome: Novelis EBITDA/ton recovers to $550–$600 by FY28; India upstream margins sustain at 43–45%; net debt/EBITDA stabilizes at 1.8–2.0x. $300M cost savings target met, supporting $150M+ FCF post-FY27.
TECHNOE’s topline growth hinges on digital infra scalability (INR100–400 crore revenue contribution) and EPC discipline (INR3,000–3,500 crore order intake); bottom-line accretion (INR15–75 EPS) requires hyperscaler validation and smart metering cash flows, while margins (14–50% EBITDA) reflect structural shift but face execution and policy risks.
1–2 minutes
3-Scenario Framework
📊 Base Case (50% Probability)
Key Variables: (1) Hyperscaler onboarding in Chennai/Noida by 1H FY27; (2) Smart metering execution hits 80% of 2.24M target by FY26-end. Outcome:INR3,400 crore revenue (FY26), INR15 EPS met; data center contributes INR80–100 crore (FY27). EBITDA margins stabilize at 14–15% (EPC) + 50%+ (digital). Capex funded via internal accruals; no equity dilution. Re-rating to 22–24x PE if digital infra scales.
